Cargando…

Metabolic characterization of the natural progression of chronic hepatitis B

BACKGROUND: Worldwide, over 350 million people are chronically infected with the hepatitis B virus (HBV) and are at increased risk of developing progressive liver diseases. The confinement of HBV replication to the liver, which also acts as the central hub for metabolic and nutritional regulation, e...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoeman, Johannes C., Hou, Jun, Harms, Amy C., Vreeken, Rob J., Berger, Ruud, Hankemeier, Thomas, Boonstra, Andre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902991/
https://www.ncbi.nlm.nih.gov/pubmed/27286979
http://dx.doi.org/10.1186/s13073-016-0318-8
_version_ 1782437058806022144
author Schoeman, Johannes C.
Hou, Jun
Harms, Amy C.
Vreeken, Rob J.
Berger, Ruud
Hankemeier, Thomas
Boonstra, Andre
author_facet Schoeman, Johannes C.
Hou, Jun
Harms, Amy C.
Vreeken, Rob J.
Berger, Ruud
Hankemeier, Thomas
Boonstra, Andre
author_sort Schoeman, Johannes C.
collection PubMed
description BACKGROUND: Worldwide, over 350 million people are chronically infected with the hepatitis B virus (HBV) and are at increased risk of developing progressive liver diseases. The confinement of HBV replication to the liver, which also acts as the central hub for metabolic and nutritional regulation, emphasizes the interlinked nature of host metabolism and the disease. Still, the metabolic processes operational during the distinct clinical phases of a chronic HBV infection—immune tolerant, immune active, inactive carrier, and HBeAg-negative hepatitis phases—remains unexplored. METHODS: To investigate this, we conducted a targeted metabolomics approach on serum to determine the metabolic progression over the clinical phases of chronic HBV infection, using patient samples grouped based on their HBV DNA, alanine aminotransferase, and HBeAg serum levels. RESULTS: Our data illustrate the strength of metabolomics to provide insight into the metabolic dysregulation experienced during chronic HBV. The immune tolerant phase is characterized by the speculated viral hijacking of the glycerol-3-phosphate–NADH shuttle, explaining the reduced glycerophospholipid and increased plasmalogen species, indicating a strong link to HBV replication. The persisting impairment of the choline glycerophospholipids, even during the inactive carrier phase with minimal HBV activity, alludes to possible metabolic imprinting effects. The progression of chronic HBV is associated with increased concentrations of very long chain triglycerides together with citrulline and ornithine, reflective of a dysregulated urea cycle peaking in the HBV envelope antigen-negative phase. CONCLUSIONS: The work presented here will aid in future studies to (i) validate and understand the implication of these metabolic changes using a thorough systems biology approach, (ii) monitor and predict disease severity, as well as (iii) determine the therapeutic value of the glycerol-3-phosphate–NADH shuttle. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13073-016-0318-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4902991
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49029912016-06-12 Metabolic characterization of the natural progression of chronic hepatitis B Schoeman, Johannes C. Hou, Jun Harms, Amy C. Vreeken, Rob J. Berger, Ruud Hankemeier, Thomas Boonstra, Andre Genome Med Research BACKGROUND: Worldwide, over 350 million people are chronically infected with the hepatitis B virus (HBV) and are at increased risk of developing progressive liver diseases. The confinement of HBV replication to the liver, which also acts as the central hub for metabolic and nutritional regulation, emphasizes the interlinked nature of host metabolism and the disease. Still, the metabolic processes operational during the distinct clinical phases of a chronic HBV infection—immune tolerant, immune active, inactive carrier, and HBeAg-negative hepatitis phases—remains unexplored. METHODS: To investigate this, we conducted a targeted metabolomics approach on serum to determine the metabolic progression over the clinical phases of chronic HBV infection, using patient samples grouped based on their HBV DNA, alanine aminotransferase, and HBeAg serum levels. RESULTS: Our data illustrate the strength of metabolomics to provide insight into the metabolic dysregulation experienced during chronic HBV. The immune tolerant phase is characterized by the speculated viral hijacking of the glycerol-3-phosphate–NADH shuttle, explaining the reduced glycerophospholipid and increased plasmalogen species, indicating a strong link to HBV replication. The persisting impairment of the choline glycerophospholipids, even during the inactive carrier phase with minimal HBV activity, alludes to possible metabolic imprinting effects. The progression of chronic HBV is associated with increased concentrations of very long chain triglycerides together with citrulline and ornithine, reflective of a dysregulated urea cycle peaking in the HBV envelope antigen-negative phase. CONCLUSIONS: The work presented here will aid in future studies to (i) validate and understand the implication of these metabolic changes using a thorough systems biology approach, (ii) monitor and predict disease severity, as well as (iii) determine the therapeutic value of the glycerol-3-phosphate–NADH shuttle. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13073-016-0318-8) contains supplementary material, which is available to authorized users. BioMed Central 2016-06-10 /pmc/articles/PMC4902991/ /pubmed/27286979 http://dx.doi.org/10.1186/s13073-016-0318-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Schoeman, Johannes C.
Hou, Jun
Harms, Amy C.
Vreeken, Rob J.
Berger, Ruud
Hankemeier, Thomas
Boonstra, Andre
Metabolic characterization of the natural progression of chronic hepatitis B
title Metabolic characterization of the natural progression of chronic hepatitis B
title_full Metabolic characterization of the natural progression of chronic hepatitis B
title_fullStr Metabolic characterization of the natural progression of chronic hepatitis B
title_full_unstemmed Metabolic characterization of the natural progression of chronic hepatitis B
title_short Metabolic characterization of the natural progression of chronic hepatitis B
title_sort metabolic characterization of the natural progression of chronic hepatitis b
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902991/
https://www.ncbi.nlm.nih.gov/pubmed/27286979
http://dx.doi.org/10.1186/s13073-016-0318-8
work_keys_str_mv AT schoemanjohannesc metaboliccharacterizationofthenaturalprogressionofchronichepatitisb
AT houjun metaboliccharacterizationofthenaturalprogressionofchronichepatitisb
AT harmsamyc metaboliccharacterizationofthenaturalprogressionofchronichepatitisb
AT vreekenrobj metaboliccharacterizationofthenaturalprogressionofchronichepatitisb
AT bergerruud metaboliccharacterizationofthenaturalprogressionofchronichepatitisb
AT hankemeierthomas metaboliccharacterizationofthenaturalprogressionofchronichepatitisb
AT boonstraandre metaboliccharacterizationofthenaturalprogressionofchronichepatitisb